3 recruiting, 1 active not recruiting, 1 enrolling by invitation. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
Follow A2 Biotherapeutics Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products No additional intervention administered in this long term follow-up study - Solid Tumor Cancer, Solid Tumor, Unspecified, Adult | Enrolling by invitation | A2 Biotherapeutics Inc. | 400 | 2025-07-31 | 2026-05-20 | |
| A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression A2B395, xT CDx with HLA-LOH assay - Solid Tumor, Adult, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | A2 Biotherapeutics Inc. | 240 | 2025-05-22 | 2025-09-09 |
| A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression A2B694, A2B543, xT CDx with HLA-LOH Assay - Solid Tumor, Adult, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | A2 Biotherapeutics Inc. | 474 | 2024-04-03 | 2026-06-12 |
| A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression A2B530, xT-Onco with HLA-LOH Assay - Solid Tumor, Adult, Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | A2 Biotherapeutics Inc. | 160 | 2023-04-28 | 2025-04-25 |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing - Solid Tumor, Adult, Colorectal Cancer | Recruiting | A2 Biotherapeutics Inc. | 500 | 2021-10-29 | 2026-10-26 |
Carcinoma, Non-Small-Cell Lung (5) · Colorectal Neoplasms (5) · Neoplasms (4) · Pancreatic Neoplasms (4) · Carcinoma, Renal Cell (3) · Kidney Neoplasms (3) · Mesothelioma (3) · Ovarian Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Colonic Neoplasms (2) · Lung Neoplasms (2) · Mesothelioma, Malignant (2) · Rectal Neoplasms (2) · Recurrence (2) · Squamous Cell Carcinoma of Head and Neck (2)
United States (5)
Eric Ng, MD (2) · John Welch, MD, PhD (2) · Eric W Ng, MD, FAAP (1)